title: Myriocin significantly increases the mortality of a non-mammalian model host during Candida pathogenesis.
abstract: Candida albicans is a major human pathogen whose treatment is challenging due to antifungal drug toxicity, drug resistance and paucity of antifungal agents available. Myrocin (MYR) inhibits sphingosine synthesis, a precursor of sphingolipids, an important cell membrane and signaling molecule component. MYR also has dual immune suppressive and antifungal properties, potentially modulating mammalian immunity and simultaneously reducing fungal infection risk. Wax moth (Galleria mellonella) larvae, alternatives to mice, were used to establish if MYR suppressed insect immunity and increased survival of C. albicans-infected insects. MYR effects were studied in vivo and in vitro, and compared alone and combined with those of approved antifungal drugs, fluconazole (FLC) and amphotericin B (AMPH). Insect immune defenses failed to inhibit C. albicans with high mortalities. In insects pretreated with the drug followed by C. albicans inoculation, MYR+C. albicans significantly increased mortality to 93% from 67% with C. albicans alone 48 h post-infection whilst AMPH+C. albicans and FLC+C. albicans only showed 26% and 0% mortalities, respectively. MYR combinations with other antifungal drugs in vivo also enhanced larval mortalities, contrasting the synergistic antifungal effect of the MYR+AMPH combination in vitro. MYR treatment influenced immunity and stress management gene expression during C. albicans pathogenesis, modulating transcripts putatively associated with signal transduction/regulation of cytokines, I-kappaB kinase/NF-kappaB cascade, G-protein coupled receptor and inflammation. In contrast, all stress management gene expression was down-regulated in FLC and AMPH pretreated C. albicans-infected insects. Results are discussed with their implications for clinical use of MYR to treat sphingolipid-associated disorders.
authors.affiliation: College of Medicine, Swansea University, Singleton Park, Swansea, United Kingdom.
authors.forename: Nadja Rodrigues
authors.initials: NR
authors.lastname: de Melo
authors.forename: Ahmed
authors.initials: A
authors.lastname: Abdrahman
authors.forename: Carolyn
authors.initials: C
authors.lastname: Greig
authors.forename: Krishnendu
authors.initials: K
authors.lastname: Mukherjee
authors.forename: Catherine
authors.initials: C
authors.lastname: Thornton
authors.forename: Norman A
authors.initials: NA
authors.lastname: Ratcliffe
authors.forename: Andreas
authors.initials: A
authors.lastname: Vilcinskas
authors.forename: Tariq M
authors.initials: TM
authors.lastname: Butt
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects* / Q000494:pharmacology; D002176:Candida albicans; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D004195:Disease Models, Animal; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007814:Larva / Q000378:metabolism / Q000382:microbiology; D051379:Mice; D009036:Moths / Q000378:metabolism* / Q000382:microbiology*
chemical_list: D000935:Antifungal Agents; D005229:Fatty Acids, Monounsaturated; C001996:thermozymocidin